Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter.

Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA 3rd, Yamamoto M, Alvarez RD, Curiel DT.

Gene Ther. 2004 Apr;11(7):645-8. Erratum in: Gene Ther. 2006 Feb;13(4):374. Yamaoto, M [corrected to Yamamoto, M].

PMID:
15029227
2.

Viral mediated gene therapy for the management of metastatic thyroid carcinoma.

DeGroot LJ, Zhang R.

Curr Drug Targets Immune Endocr Metabol Disord. 2004 Sep;4(3):235-44. Review.

PMID:
15379725
3.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
4.

Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors.

Rots MG, Curiel DT, Gerritsen WR, Haisma HJ.

J Control Release. 2003 Feb 21;87(1-3):159-65. Review.

PMID:
12618032
5.

Adenoviral vectors for liver-directed gene therapy.

Connelly S.

Curr Opin Mol Ther. 1999 Oct;1(5):565-72. Review.

PMID:
11249663
6.

Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).

Bauerschmitz GJ, Barker SD, Hemminki A.

Int J Oncol. 2002 Dec;21(6):1161-74. Review.

PMID:
12429964
7.

Telomerase promoter-driven cancer gene therapy.

Gu J, Fang B.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S64-70. Review.

PMID:
14508082
8.

Head and neck cancer: gene therapy approaches. Part 1: adenoviral vectors.

Nemunaitis J, O'Brien J.

Expert Opin Biol Ther. 2002 Feb;2(2):177-85. Review.

PMID:
11849117
9.

Results of retroviral and adenoviral approaches to cancer gene therapy.

Yin LH, Fu SQ, Nanakorn T, Garcia-Sanchez F, Chung I, Cote R, Pizzorno G, Hanania E, Heimfeld S, Crystal R, Deisseroth A.

Stem Cells. 1998;16 Suppl 1:247-50. Review.

10.

Adenoviral vectors: systemic delivery and tumor targeting.

Green NK, Seymour LW.

Cancer Gene Ther. 2002 Dec;9(12):1036-42. Review.

11.

Conditionally replicative adenoviruses for ovarian cancer therapy.

Barnes MN, Coolidge CJ, Hemminki A, Alvarez RD, Curiel DT.

Mol Cancer Ther. 2002 Apr;1(6):435-9. Review.

12.

Emerging new therapies for chemotherapy-resistant cancer using adenoviral vectors.

Nemunaitis J, Cunningham C.

Drug Resist Updat. 2002 Feb;5(1):34-46. Review.

PMID:
12127862
13.

Transductional and transcriptional targeting of adenovirus for clinical applications.

Glasgow JN, Bauerschmitz GJ, Curiel DT, Hemminki A.

Curr Gene Ther. 2004 Mar;4(1):1-14. Review.

PMID:
15032610
14.

Gene therapy targeting in the central nervous system.

BenĂ­tez JA, Segovia J.

Curr Gene Ther. 2003 Apr;3(2):127-45. Review.

PMID:
12653406
15.

Transcriptional targeting for ovarian cancer gene therapy.

Casado E, Nettelbeck DM, Gomez-Navarro J, Hemminki A, Gonzalez Baron M, Siegal GP, Barnes MN, Alvarez RD, Curiel DT.

Gynecol Oncol. 2001 Aug;82(2):229-37. Review.

PMID:
11531272
16.

Conditional gene targeting for cancer gene therapy.

Haviv YS, Curiel DT.

Adv Drug Deliv Rev. 2001 Dec 17;53(2):135-54. Review.

PMID:
11731024
17.

Gene therapy for superficial bladder cancer.

Rosser CJ, Benedict WF, Dinney CP.

Expert Rev Anticancer Ther. 2001 Dec;1(4):531-9. Review.

PMID:
12113085
18.

Targeting gene therapy vectors to CNS malignancies.

Spear MA, Herrlinger U, Rainov N, Pechan P, Weissleder R, Breakefield XO.

J Neurovirol. 1998 Apr;4(2):133-47. Review.

PMID:
9584951
19.

Strategies for cancer gene therapy using adenoviral vectors.

Descamps V, Duffour MT, Mathieu MC, Fernandez N, Cordier L, Abina MA, Kremer E, Perricaudet M, Haddada H.

J Mol Med (Berl). 1996 Apr;74(4):183-9. Review.

PMID:
8740649
20.

Gene therapy of gliomas: receptor and transcriptional targeting.

Spear MA.

Anticancer Res. 1998 Sep-Oct;18(5A):3223-31. Review.

PMID:
9858886

Supplemental Content

Support Center